change language

language

BGI Genomics Gains CE Certification for EU Market for In Vitro Diagnostics Product
Dou Shicong
DATE:  Dec 06 2017
/ SOURCE:  Yicai
BGI Genomics Gains CE Certification for EU Market for In Vitro Diagnostics Product BGI Genomics Gains CE Certification for EU Market for In Vitro Diagnostics Product

(Yicai Global) Dec. 6 -- China's biggest genome sequencing firm BGI Genomics Co. [SHE:300676] has obtained a CE Certification from the British Standards Institution for its vitro diagnostics product, representing the first time it has met EU market requirements.

The certificate for the product, a test agent to determine if a fetus chromosome is a whole body, will run to June 2020, the firm's European unit said in a press briefing yesterday. Fetal chromosomes that are not a whole body can cause serious congenital diseases including Down's Syndrome.

The CE certification provides the products with legal status for entry into the EU market, which is conducive to improving the company's market competitiveness in the reproductive health field, BGI Genomics said.

Established in 1999, BGI Genomics supplies products and services covering the entire gene sequencing industry chain, including upstream sequencers and reagents and downstream GS services.

Follow Yicai Global on
Keywords:   BGI Genomics,CE Certification,BSI,Down's Syndrome